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Abstract
Advances in genomic sequencing technology have raised fundamental challenges to the traditional 
ways genomic information is communicated. These challenges will become increasingly complex 
and will affect a much larger population in the future if genomics is incorporated into standard 
newborn screening practice. Clinicians, public health officials, and other stakeholders will need to 
agree on the types of information that they should seek and communicate to parents. Currently, 
few evidence-based and validated tools are available to support parental informed decision-
making. These tools will be necessary as genomics is integrated into clinical practice and public 
health systems. In this article we describe how the North Carolina Newborn Exome Sequencing 
for Universal Screening study is addressing the need to support parents in making informed 
decisions about the use of genomic testing in newborn screening. We outline the context for 
newborn screening and justify the need for parental decision support. We also describe the process 
of decision aid development and the data sources, processes, and best practices being used in 
development. By the end of the study, we will have an evidenced-based process and validated tools 
to support parental informed decision-making about the use of genomic sequencing in newborn 
screening. Data from the study will help answer important questions about which genomic 
information ought to be sought and communicated when testing newborns.
Address correspondence to Megan A. Lewis, PhD, 3040 Cornwallis Rd, PO Box 12194, Research Triangle Park, NC 27709-2194. 
melewis@rti.org. 
Dr Lewis led the decision aid development and drafted the initial manuscript; Dr Paquin assisted with decision aid development and 
helped draft the initial manuscript; Ms Roche, Dr Furberg, and Dr Rini assisted with decision aid development and reviewed and 
revised the manuscript; Drs Berg, Powell, and Bailey advised on decision aid development and reviewed and revised the manuscript; 
and all authors approved the final manuscript as submitted.
POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
HHS Public Access
Author manuscript
Pediatrics. Author manuscript; available in PMC 2016 June 27.
Published in final edited form as:
Pediatrics. 2016 January ; 137(Suppl 1): S16–S23. doi:10.1542/peds.2015-3731E.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The North Carolina Newborn Exome Sequencing for Universal Screening (NC NEXUS) 
study is 1 of 4 centers funded by the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development and the National Human Genome Research Institute to 
study the implications and challenges of generating and using genomic sequencing 
information in the newborn period. The NC NEXUS study includes several interrelated 
projects that seek to evaluate whether genome-scale next-generation sequencing (NGS) can 
extend the utility of newborn screening (NBS) by using whole exome sequencing (WES) 
technology, devise and evaluate a clinically oriented framework for the analysis of next-
generation sequencing newborn screening (NGS-NBS), and identify and investigate critical 
ethical, legal, and social implications (ELSI) that arise when families are asked to make 
decisions about which categories of information generated from this technology that they 
want to learn. Taken together, we expect that these projects will provide valuable empirical 
data that help clinicians and families make informed decisions about these complex issues.
Our investigation of the ELSI issues generated from the application of genomic sequencing 
in newborns includes studies to support the development of a decision aid for parents facing 
decisions about learning NGS-NBS results, development of a tablet-based decision aid based 
on best practices and user design principles, and implementation of the decision aid in a 
randomized controlled trial (RCT). Parents who have a newborn or a child aged ≤5 years 
that has been diagnosed with a genetic disorder will take part in the RCT and use the 
decision aid, in conjunction with clinical consultation, to help them decide whether they 
want to have their child’s exome sequenced. If they agree to sequencing, they will also 
decide which types of genomic information they want to learn from this analysis. All parents 
electing to have their child’s genes sequenced will learn clinically relevant genomic findings 
in genes implicated in the conditions currently screened for on standard NBS panels in the 
United States. In addition, genes implicated in other disorders with similar characteristics 
but for which screening is not currently available will also be analyzed and results returned. 
These disorders are all medically actionable during childhood and can potentially be 
prevented, ameliorated, or treated more effectively if detected early. A subgroup of parents 
will be randomly assigned to make decisions about learning additional genomic information 
for conditions that do not meet our criteria for actionability or age of onset. The 3 additional 
information categories being studied in NC NEXUS are carrier status for recessive disorders, 
adult-onset medically actionable conditions, and childhood-onset disorders that are not 
medically actionable. Parents randomly assigned to this “decision arm” of the study can 
decide to learn all, some, or none of these categories of additional findings. Parental 
outcomes will be monitored by standardized measures over a 3-month follow-up period to 
elucidate the effect of making these decisions.
In this article we provide the context for the NC NEXUS study, describe the development 
process of the parental decision aid, and analyze the key ELSI issues raised and addressed in 
the study (Table 1). Asking parents to make informed decisions about the types of 
information they want to learn and providing a decision aid to support them in this decision-
making process are 2 unique aspects of the study. We highlight the key innovations of our 
approach, explain the theoretical bases for the decision aid, and describe the research and 
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formative work that have guided its development. We conclude with an overview of our 
plans for the next steps in the study.
 THE NBS CONTEXT FOR NC NEXUS
The introduction of tandem mass spectrometry (MS/MS) significantly broadened the range 
of disorders that are detected by routine NBS. As a result, there are many conditions that can 
be detected with this biochemical screening that do not meet traditional screening criteria.1 
MS/MS provides a glimpse of the shifts in practice and policy that will be needed to 
accommodate population-level genome sequencing, albeit on a much smaller scale than 
what will be needed as sequencing technology becomes increasingly incorporated.
In response to the challenges raised by the use of MS/MS, a national committee convened by 
the American College of Medical Genetics and Genomics reached consensus on 
characteristics of disorders that would qualify them for inclusion on a state’s NBS panel and 
recommended a panel of 29 conditions for which there was strong agreement on expected 
benefits.2 They also recommended 25 additional “secondary targets,” conditions for which 
there was less agreement about benefit (eg, very rare conditions, no current treatment) but 
that would also be identified by the use of MS/MS. This decision altered a fundamental 
precedent in NBS as information about a range of conditions, including those that did not 
meet criteria and that were incidental to the initial purpose of screening, would be returned 
to parents. The use of WES or other genomic technologies will inevitably produce an even 
greater amount of secondary information and, while enhancing the promise of more efficient 
disease identification,3 will raise concerns about a wide spectrum of issues.4–8
One central question is how to define which characteristics define an appropriate return of 
results, in light of the fact that genomescale sequencing will identify information that goes 
far beyond the original purpose of screening. Some of this information will be medically 
actionable, but most will not. Defining the criteria for determining what information will be 
sought and disclosed will be one of the most vexing challenges facing clinicians and policy 
makers, as will the inevitable need to provide parents with decision support to help them 
determine which types of information they want to learn. These issues, though relevant to 
the ethical application of NGS technologies to any age group, become particularly 
heightened and gain complexity when applied to newborns. Policy recommendations 
generally conclude that testing done in asymptomatic minors should occur only when timely 
identification can prevent harm and will directly benefit the infant.9
When those criteria are met, policymakers and courts in the United States have decided that 
NBS can be performed without explicit parental consent. The underlying assumption is that 
the urgent need to treat identified infants outweighs the ethical stipulation to obtain parental 
consent. But genome-scale testing such as WES challenges this “public health emergency” 
approach to NBS, leading many ethicists and clinicians to suggest that these technologies, 
and the breadth of information they can potentially provide, will force a reevaluation of 
current screening practice and strengthen the case for obtaining parental informed 
consent.4,10 Parents typically receive some information about NBS, and in many states they 
can opt out for religious or moral reasons. The fact that very few decline can be construed as 
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tacit acceptance of the need for rapid action at the cost of parental autonomy.11 Asking 
parents to make informed decisions about a range of results for different categories of 
conditions before testing represents a fundamental shift in how public health NBS programs 
are conducted. The logistical constraints posed by the timing and context of NBS will 
require new models, tools, and data to accommodate this shift in practice. There are few 
investigations examining the impact of decision-making on parents, and little evidence exists 
to show how they respond after learning results. Empirical data on these topics are critical 
for informing policy and practice, and collecting and assessing them will be a major 
contribution of the project.
 VALIDATED METHODS ARE NEEDED TO HELP PARENTS MAKE 
INFORMED DECISIONS
Validated methods to support parental decision-making are urgently needed to inform 
changes in policy and practice in NBS. Parents need to be actively engaged in decision-
making to enable them to make decisions consistent with their personal values. One major 
challenge to developing such decision tools is that both the general population12–14 and most 
primary care physicians have limited knowledge about genomics15 and the kinds of 
information that can be learned. Existing materials describing NBS usually take the form of 
short brochures, which have generally not been subjected to formal evaluation to determine 
their effectiveness in conveying basic information about NBS16 or their value in educating 
parents about controversial topics such as blood spot retention for research purposes.17 
Introducing genomescale sequencing in NBS would quickly render current informational 
materials obsolete. State programs could no longer ethically justify materials that simply list 
and describe the disorders included on a screening panel. Teaching parents how new 
sequencing technologies expand the amount and range of potential NBS results would be 
better achieved by a consent process that facilitates informed decisionmaking. Parental 
decisions about the kinds of information they want to learn about their child could be 
enabled by an online process that, in conjunction with clinical consultation when needed, 
would help them make decisions consistent with their beliefs and values. Decision aid 
design requires the flexibility to adapt to rapidly evolving knowledge about the conditions 
screened yet be easily disseminated to large populations. These specifications favor the 
development of electronically based tools that retain their usefulness across multiple digital 
platforms (eg, mobile phones, tablets, or personal computers), allowing a rapid response to 
changing information and making large-scale dissemination feasible.
 OVERVIEW OF NC NEXUS DECISION AID DEVELOPMENT
The decision aid is a tablet-optimized, responsive Web application that dynamically delivers 
tailored multimedia content through an interface integrating animated multimedia, 
interactive tasks, and touchscreen gestural controls (eg, swipe, tap, drag, pinch). It is being 
developed based on communication principles, input from a multidisciplinary committee of 
experienced genomic clinicians who are “binning” (categorizing) variant information,18,19 
data from qualitative interviews conducted with parents, findings from a discrete choice 
experiment, existing literature on user-centered design principles, and best practices for 
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developing decision aids. The NC NEXUS steering committee, composed of communication 
researchers, behavioral scientists, geneticists, genetic counselors, and ethicists, provides 
regular input on design and content. Here, we review some of the communication challenges 
and data sources that are helping us address the ELSI questions shown in Table 1 and that 
are informing development of the decision aid.
 How Will Information About Genomic Sequencing Be Presented to Parents in an 
Understandable Way That Leverages Clinician Experience?
One important challenge that must be addressed is how to communicate the enormous scope 
of information generated by genomic sequencing, when the majority is currently 
uninterpretable and therefore would not be returned to parents.20 Even the loci clearly 
associated with recognizable phenotypes often lack clinical utility, especially when 
identified in childhood, which increases the complexity of both communicating this 
information to a lay audience and the decision-making by parents. Anticipating these 
challenges, we are using a framework that defines categories of information based on 
medical actionability and age of onset, which could potentially be returned in real-world 
settings in the future and outside a research context. We are building on a semiquantitative 
metric developed by investigators in our research group to help define medical actionability. 
The systematic evidence review and rating of variants by clinicians, geneticists, and genetic 
counselors characterize the actionability of a condition based on its potential severity, 
likelihood of occurrence, efficacy of interventions, acceptability or burdens of intervention, 
and knowledge base.19 Scores on these dimensions are combined in an algorithm to 
determine medical actionability. These actionability scores are plotted against the predicted 
age of onset of the disorder. This age-based metric system leads to variants being 
categorized in 4 “bins”: (1) conditions similar to those detected through NBS (ie, conditions 
that are medically actionable and have onset of symptoms or interventions in childhood); (2) 
conditions with a childhood onset that are not medically actionable; (3) conditions with an 
adult onset that are medically actionable; and (4) conditions with an adult onset that are not 
medically actionable. All parents who agree to sequencing can decide to learn results from 
bin 1; parents in the randomized group will be able to request information from bins 2 and 3 
as well as findings consistent with carrier status for recessive disorders. Loci associated with 
bin 4 will not be analyzed. We anticipate that the systematic categorization of the vast 
amount of information potentially available in a way that accounts for age of onset and 
actionability will help address controversies about the information’s degree of clinical utility 
and the degree of personal utility; the latter may be of most relevance to parents making 
these decisions. This framework can accommodate an expanded knowledge base as 
conditions can be classified differently in the scheme without significant changes to the 
decision aid’s functioning.
 How Can Parental Input Be Incorporated to Improve How Information About Genomic 
Sequencing Is Presented?
We are using a multimethod approach to ascertain parents’ values, beliefs, and knowledge 
about NGS, NBS, and genomic sequencing.
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 Formative Interviews With Parents—We recruited 33 couples who were married or 
in a committed relationship to participate in dyadbased interviews.21 Approximately half the 
couples were pregnant at the time of the interview or had a recent birth within the past 12 
months. The other half had undergone genetic testing for their newborn or young child (ages 
≤5 years). These 2 subgroups are similar to parents who will be recruited for the NC 
NEXUS RCT. The purpose of these semistructured interviews was to examine how couples 
communicate with each other and make decisions about genomic screening results for their 
child. We also used the interviews as a mechanism for gathering feedback on early drafts of 
decision aid materials.
A majority of parents showed individual variability in decisions across categories, NGS-
NBS, medically actionable adult onset, carrier status, and non–medically actionable 
childhood conditions, suggesting that they saw meaningful differences between the types of 
conditions for which results might be returned.22 Regarding couple-level decisions, many 
couples described a deliberate, collaborative process of talking together and weighing the 
pros and cons before making joint decisions across all the results categories.21 The majority 
of participants said they would find the decision harder to make alone because their partner 
offered support, reassurance, input, or alternative perspectives.
With this in mind, we designed the decision aid to support a parental shared decision-
making approach, where both members of the couple can complete the decision aid together 
and make joint decisions. Moreover, we organized the decision aid content around the same 
result categories that participants will be asked to decide about and allowed them to learn 
about and make separate decisions for each category. In addition, we used important values 
and concerns parents shared as content in the decision aid for a value clarification exercise.
 Discrete Choice Experiment—To better understand how different characteristics of 
genetic disorders influence parental preferences for requesting additional non–medically 
actionable information about their child, we conducted a discrete choice experiment with 
1289 parents of young children ages ≤5 years.23 To facilitate subgroup analyses, we 
stratified the sample equally by race (white and African American) and gender. We 
randomly assigned each participant to complete a set of 8 choice tasks. In these tasks, we 
showed participants a pair of hypothetical profiles describing different kinds of sequencing 
results and asked them to select the profile they believed would be more important to know. 
The profiles in this experiment were designed by altering the levels of 7 characteristics: the 
likelihood the condition would develop given a true-positive result, the age of onset, level of 
mental disabilities, level of physical disabilities, the rate of disease progression, availability 
of options to improve quality of life, and the relative impact on life span of the child. This 
approach allowed us to estimate the relative influence of each characteristic by examining 
the choices that parents made in a controlled setting. Participants were also asked to 
complete basic demographic questions and questions that measured the level of distress they 
associated with specific characteristics of the genetic disorders.
We found that among the 7 characteristics parents considered, the likelihood the condition 
would develop given a true-positive test result was the most important characteristic in 
predicting whether a parent thought the information was important to know. The availability 
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of options to improve quality of life was the only characteristic that did not significantly 
influence which profiles were chosen. Also, within each characteristic, participants rated the 
more severe levels as more distressing (eg, a rapid vs slow progression of the disease). This 
information is helping us choose exemplary disorders to use in the decision aid.
 How Can Parental Informed Decision-Making in the NC NEXUS Study Be Best 
Supported?
Our study asks parents to make decisions about potential future health events that are 
uncertain. These are difficult, and possibly emotional, decisions for parents to make. 
Theories of decision-making24,25 suggest that in these circumstances it is more important 
that people understand the gist of the information than being able to recall verbatim the risk 
estimates or other information presented. However, a balanced presentation of the pros and 
cons of sequencing and the risk of disease is still needed. These decisions are akin to many 
current medical decision-making scenarios for which evidence for the best course of 
treatment or action is equivocal. In these cases, an optimal decision can be reached by 
informed and shared decision-making processes.26
Decision aids are educational interventions that can help parents make better decisions by 
providing information and helping to clarify values and preferences. They are particularly 
helpful when there is no clear best choice for action.27 Evidence shows that decision aids 
increase knowledge,28,29 promote more accurate risk perceptions,30 support value-congruent 
decisions when there is a value clarification component, and reduce decisional conflict while 
increasing decision confidence.31
Decision aids can be designed to promote informed decisions that do not necessarily involve 
a clinician or promote shared decision-making between a parent and clinician.32 Our 
decision aid exemplifies the latter type, because parents will have the opportunity to consult 
with a genetic counselor to answer questions and to discuss their decisions about genomic 
sequencing for their child and the types of information they decide to learn. Informed 
decision-making by parents is a necessary component of shared decision-making that might 
occur in these interactions.32
The process of informed decision-making requires that parents understand the potential 
application of NGS to future health conditions, understand the evidence about the risks and 
benefits for all decision options, and consider their own values and preferences when 
deciding on a course of action.33,34 The NC NEXUS decision aid applied standards 
described by the International Patient Decision Aid Standards checklist (http://
www.ipdas.ohri.ca/IPDAS_checklist.pdf). One challenge of applying these standards is that 
some of the dimensions required by the International Patient Decision Aid Standards are not 
currently known and will require additional study by the NC NEXUS study and others. 
Another challenge is that the standards are usually applied to decisions about a single piece 
of information rather than decisions about categories of information (eg, carrier status). 
Future iterations of the decision aid can be updated as evidence from NC NEXUS and other 
studies emerges.
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We are also developing and testing a new model for informed decisionmaking that includes 
both members of a couple in the decision-making process by integrating traditional notions 
of shared decision-making between clinicians and patients35,36 with dyadic theories of 
decision-making and behavior that are typically applied to close relationships.37 This 
integration is important because genomic sequencing has great potential to provide results 
with implications for both sides of the family. In our previous study of fragile X NBS, our 
institutional review board required consent from both parents; consequently, we conducted 
an extensive investigation of the fathers’ role in these decisions and developed an algorithm 
for applying the institutional review board’s “reasonably available” guideline for fathers’ 
consent.38 There are few theoretical accounts to help guide collaborative joint decisions 
between parents and inform future research and practice. Our study will assess whether the 
processes of shared, informed decision-making helps to attenuate potential negative 
psychological consequences of being asked to make decisions about genomic information. 
However, we will also recruit single participants (when the father or mother is not 
“reasonably available”) and samegender couples to understand decision-making and 
consequences, regardless of relationship type.
 User-Centered Design Principles—Principles of user-centered design require 
iterative audience involvement and pretesting39 throughout the decision aid development 
process, which typically consists of 4 major activities: content development, decision aid 
design and programming, pretesting, and experimental study. We used a feature-driven 
development approach in which major components of the decision aid were initially 
developed and tested, then refined, progressively integrated, and tested again under 
controlled conditions throughout the development life cycle. First, we created the content for 
the decision aid that was extensively reviewed by the steering committee. We then developed 
artwork, audio narration, and other multimedia elements that were integrated into the 
application. This process used key user interface and user experience design principles such 
as giving the user control, empowering the user, and allowing exploration and browsing; 
reducing the user’s memory load by providing context and reminders, with minimal reliance 
on the need for recall; providing immediate feedback and the option of help at any point, 
including defining the terminology used; and keeping the interface consistent, with active 
buttons or menus in the same place throughout.40 The NC NEXUS decision aid allows users 
to go at their own pace, repeating and reviewing information as needed. All content uses 
plain-language principles to address the varying health literacy levels of the audience.
Usability testing of the decision aid has involved conducting interviews with a small group 
of people who are in the same age range as our intended end users, using a think-aloud 
interviewing method41 to solicit feedback and assess the technical functionality. Results 
from these interviews informed decision aid development to make it more understandable 
and engaging.
 Expert and Clinician Input for Accuracy
At various stages during the development of the decision aid, we have sought input and 
advice from experts and experienced clinicians. Stakeholder engagement with key groups of 
experts has provided critical feedback on issues to be discussed with parents and guidance 
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on decision aid content. For example, we have established a continuous dialogue with the 
NC NEXUS steering committee, comprising researchers with expertise in communication 
and behavioral science, medical genetics, genetic counseling, pediatrics, and bioethics. In 
addition to informing the research questions explored through other formative research 
projects already described, the steering committee has directly shaped the structure and 
content of the decision aid. In the early phases of development, we met with the steering 
committee to review a general outline of the decision aid content and established the 
technical requirements needed for data transfer and participant tracking throughout the 
study. Later, the steering committee played instrumental roles in editing the decision aid’s 
content for technical accuracy and expected patient literacy and in finalizing a complete 
draft of the shooting script, including full text of the audio narration and detailed notes 
describing multimedia elements to appear on screen. The steering committee’s input proved 
invaluable for striking a balance in crafting a factual overview of the complex topics of 
genomic sequencing and issues related to returning different kinds of results while using 
plain-language principles.
 NC NEXUS NEXT STEPS
The NC NEXUS study will allow us to test the extent to which a decision aid supports 
informed decision-making; reduces decision conflict, regret, or distress; and increases 
decision confidence. It will also allow us to evaluate whether there are differences in these 
outcomes for parents who receive information from the categories of additional information 
available to them: conditions that have childhood onset but are not medically actionable, 
disorders that have adult onset and are medically actionable, and carrier status findings. We 
will also be able to detect differences between parents who make decisions about a newborn 
child versus an older child with a previously diagnosed genetic disorder.
Because the decision aid is electronically based, it will be adaptable as new evidence 
emerges about genetic conditions. It will be easily updateable to keep pace with best 
practices in decision aid development and the communication of genomic information. We 
will also gain a much greater understanding of how parents understand genomic sequencing, 
their perceptions of the decisions they make, the role and impact of a decision aid in clinical 
interactions, and the ramifications of result disclosure for family adaptation. This 
information will be used to update and refine the content presented.
After the project is completed, we will have validated materials produced by an evidence-
based process that could be used in other studies and in clinical care to support parents and 
pediatricians as they make decisions about genomic sequencing. We will also have collected 
evidence to address key questions about the degree to which parents and children are harmed 
by or have benefitted from learning the information offered in NC NEXUS. Answering these 
questions will be critical to help inform policy and clinical practice about how genomic 
information is best communicated in various clinical, public health, and research settings.
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TABLE 1
ELSI Questions Raised by the Use of Genome-Scale Sequencing in NBS and How They Are Addressed in NC 
NEXUS
ELSI Question NC NEXUS Approach
How can the vast amount of genomic information be 
categorized into meaningful units to facilitate parental 
decision-making and support clinicians?
Categorize disparate conditions based on age of onset and medical 
actionability.
How can parental input be incorporated to improve how 
information about genomic sequencing is presented?
Conduct multimethod research (qualitative methods and discrete choice 
experiment) and triangulate data to understand parental needs, preferences, 
values, and the impact of their decisions.
How can parental informed decision-making in the NC 
NEXUS study be best supported?
Develop a decision aid to support parental decision-making that incorporates 
best practices and is scalable to a broad population.
To what degree will parents and their children be harmed or 
benefited when asked to make decisions about which 
information to learn following genome-scale sequencing?
Conduct an RCT to understand the short- and long-term effects of parental 
decision-making about a broad range of information spanning a spectrum of 
age of onset and actionability.
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